What it is
Exenatide holds a specific place in the story of these drugs: it was the first GLP-1 receptor agonist ever approved. It’s an incretin mimetic — a medication that copies the action of the gut hormone GLP-1, prompting the body to release insulin when blood sugar is high and helping to blunt appetite. It comes in two forms: Byetta, a twice-daily injection, and Bydureon, a longer-acting once-weekly version.
Why it matters if you’re on (or considering) a GLP-1
Exenatide is the ancestor of the medications getting all the attention today. Understanding it helps put the newer drugs in context: semaglutide, tirzepatide, and dulaglutide all build on the same core idea of mimicking GLP-1, but with chemistry designed to last longer in the body and, in trials, produce larger effects. Compared with those, exenatide is shorter-acting and generally considered an older option — one your clinician might still choose in certain situations, but not usually the first name in the current weight-management conversation.
What to keep in mind
Exenatide is approved primarily to improve blood sugar in type 2 diabetes, not as a dedicated weight-loss treatment. Its shorter duration of action is tied to its half-life, which is part of why the twice-daily form exists at all. Like other drugs in the class, it can cause nausea and other digestive side effects, and it carries specific warnings and contraindications. None of this is a recommendation for or against it — which GLP-1 is appropriate, if any, is a decision to make with your prescriber based on your own health.